See more : Novozymes A/S (NVZMY) Income Statement Analysis – Financial Results
Complete financial analysis of Quince Therapeutics, Inc. (QNCX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quince Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Gourmet Provisions International Corporation (GMPR) Income Statement Analysis – Financial Results
- Auplata Mining Group (ALAMG.PA) Income Statement Analysis – Financial Results
- Mobileye Global Inc. (MBLY) Income Statement Analysis – Financial Results
- NACCO Industries, Inc. (NC) Income Statement Analysis – Financial Results
- Regional REIT Limited (RGL.L) Income Statement Analysis – Financial Results
Quince Therapeutics, Inc. (QNCX)
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| Gross Profit | -322.00K | -175.00K | -344.00K | -332.00K | -188.00K | -51.00K | -45.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.45M | 25.18M | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 7.48M | -997.00K | -247.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 3.48M | 1.07M | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 568.00K | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -31.26M | -52.02M | -89.97M | -78.56M | -38.98M | -12.07M | -10.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.62M | -52.02M | -90.32M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.04M | 71.00K | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -31.58M | -51.94M | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -197.00K | -284.00K | -620.00K | 2.17M | -188.00K | 357.00K | 1.87M |
| Net Income | -31.39M | -51.66M | -89.33M | -76.85M | -36.79M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| EPS Diluted | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
4,400 Shares in Cortexyme, Inc. (NASDAQ:CRTX) Acquired by TD Asset Management Inc.
TD Asset Management Inc. acquired a new stake in Cortexyme, Inc. (NASDAQ:CRTX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,400 shares of the...
Mallinckrodt BLA Submission, And Other News: The Good, Bad And Ugly Of Biopharma
Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation. Calliditas Therapeutics inks deal for Genkyotex Acquisition.
Bristol Myers Squibb NDA, And Other News: The Good, Bad And Ugly Of Biopharma
Bristol Myers Squibb resubmits multiple myeloma therapy application. Onconova reports progress of INSPIRE trial data analysis.
Stocks To Watch: Big Focus On Big Tech
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020
Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed wit
Legal & General Group Plc Trims Position in Cortexyme, Inc. (NASDAQ:CRTX)
Legal & General Group Plc lessened its stake in Cortexyme, Inc. (NASDAQ:CRTX) by 22.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,809 shares of the biopharmaceutical company’s...
V&M Premium Portfolio: 2020 Mid-Year Report Card Through Week 26
The Premium Portfolio is up +14.43% YTD, while the benchmark S&P 500 Index is down -6.86% through June 26th. The Premium Portfolio has beaten the S&P 500 every
HC Wainwright Initiates Coverage on Cortexyme (NASDAQ:CRTX)
Analysts at HC Wainwright initiated coverage on shares of Cortexyme (NASDAQ:CRTX) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $76.00 price target on the biopharmaceutical company’s stock....
Cortexyme (NASDAQ:CRTX) Stock Rating Lowered by Zacks Investment Research
Cortexyme (NASDAQ:CRTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Cortexyme Inc. is a clinical-stage biopharmaceutical company. It...
Citigroup Inc. Has $158,000 Stock Holdings in Cortexyme, Inc. (NASDAQ:CRTX)
Citigroup Inc. increased its position in Cortexyme, Inc. (NASDAQ:CRTX) by 50.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,470 shares of the biopharmaceutical...
Source: https://incomestatements.info
Category: Stock Reports